ArticleActa bio-medica : Atenei Parmensis2020
Implications of SARSr-CoV 2 infection in thalassemias: Do patients fall into the "high clinical risk" category?
Article in Acta bio-medica : Atenei Parmensis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Through the Eyes of the Recipient: Navigating Transfusion Services Amidst COVID-19 in Multi-Transfused Thalassaemic Patients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- COVID-19 and β-thalassemia: in lieu of evidence and vague nexus.Annals of hematology · 2024Review
- Review
- COVID-19 pandemic and care of transfusion-dependent patients of thalassaemia: Experience from a paediatric centre in North India.Journal of paediatrics and child health · 2022Article
- Article
- Efficacy and Safety of Sinopharm Vaccine for SARS-CoV-2 and breakthrough infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report.Mediterranean journal of hematology and infectious diseases · 2022Article
- First report of COVID-19 reinfection in a patient with beta thalassemia major.Clinical case reports · 2021Article
- Coronavirus Disease 2019 (COVID-19) Severity in Patients with Thalassemias: A Nationwide Iranian Experience.Mediterranean journal of hematology and infectious diseases · 2021Article
- [Influence of COVID-19 on the occurrence and treatment of hemolytic diseases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- A comprehensive update of ICET-A Network on COVID-19 in thalassemias: what we know and where we stand.Acta bio-medica : Atenei Parmensis · 2020Review
- Prevalence and severity of Coronavirus disease 2019 (COVID-19) in Transfusion Dependent and Non-Transfusion Dependent β-thalassemia patients and effects of associated comorbidities: an Iranian nationwide study.Acta bio-medica : Atenei Parmensis · 2020Article
- Prevalence and mortality in β-thalassaemias due to outbreak of novel coronavirus disease (COVID-19): the nationwide Iranian experience.British journal of haematology · 2020Article
- Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A Multicentre ICET-A Study.Mediterranean journal of hematology and infectious diseases · 2020Article
- Hemoglobinopathy and pediatrics in the time of COVID-19.Hematology, transfusion and cell therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We're all flying blind regarding coronavirus, but it's fair to think if thalassemic patients are particularly vulnerable to SARS-COV-2 infection or are at potential higher risk of complications from COVID-19 than normal population, specially when they become older. The frustrating thing is that, right now, this virus is still new. It only came to the attention of the World Health Organization at the end of December. Very few cases in thalassemia have so far been reported; is this due to lack of testing or a true lack of infection/susceptibility? However, we believe that more data should be collected to better characterise the impact of SARS-CoV-2 infection in patients with thalassemias. Therefore, a multicenter registry and the collection of comprehensive data from both positive COVID-19 thalassemia major and non-transfusion dependent thalassemia are necessary to clarify debated issues. In the meantime an early and vigilant monitoring along with high quality supportive care are needed in thalassemic patients at high risk for SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.